Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
Coronary vascular dysfunction is one of the "final common pathways" for the impact of
multiple cardiovascular risk factors. The investigators will conduct a randomized,
double-blind placebo-controlled study in individuals with the metabolic syndrome and baseline
coronary vascular dysfunction to evaluate the impact of vericiguat, a stimulator of soluble
guanylyl cyclase, on coronary vascular function using non-invasive cardiac magnetic resonance
imaging.